Acyclovir in children is usually associated with minimal local adverse effects, with bullous eruptions being extremely rare in occurrence. A 5-year-old boy was admitted to the pediatric intensive care unit as a case of febrile encephalopathy with status epilepticus. He was managed empirically with intravenous antibiotics and antiviral drugs (acyclovir). On day 6, he developed hemorrhagic bullae near the infusion site, which reappeared after every acyclovir infusion. No definitive cause was identified despite thorough hematological, serological, and microbiological investigations. After a meticulous literature search and application of Naranjo algorithm, acyclovir was found to be the definitive cause of the bullous eruptions.
Introduction
Acyclovir, a cyclic guanosine derivative, is a potent antiviral agent of low toxicity. It has a high specificity against herpes viruses (herpes simplex virus [HSV] 1 and HSV 2) and varicella-zoster virus. [1, 2] It is available as intravenous, oral, and topical formulations. Systemic adverse effects are rare. [3] Adverse cutaneous reactions are known to occur after acyclovir administration via any route. Local phlebitis and inflammation after intravenous infusion are common. [1, 2] However, bullous eruptions near infusion site are extremely rare, with only few cases in children reported so far in the literature. [1] Hence, here, we present a child with bullous eruption near the infusion site after acyclovir administration.
Case Report
A 5-year-old boy was admitted to the pediatric intensive care unit with febrile encephalopathy and status epilepticus. Possibility of central nervous system infection was considered, and the child was started on injection ceftriaxone empirically after performing a lumbar puncture. Cerebrospinal fluid analysis revealed raised protein levels with lymphocyte predominant pleocytosis. Computed tomography scan was suggestive of cerebral edema. The child did not show any improvement clinically, so empirical acyclovir was started intravenously at a dose of 60 mg/kg/day on day 2 of illness with viral encephalitis as a probable diagnosis. The child responded dramatically following acyclovir administration.
On day 6 of illness, the child developed hemorrhagic bullae near the infusion site [ Figure 1 ]. Subsequently, acyclovir doses were infused at a slower rate and at a different site. Still, similar bullous eruptions developed near the new infusion site as well. The bullae spontaneously ruptured leaving behind a punched-out ulcers that healed with scarring [ Figures 2 and 3 ].
The laboratory evaluation included total blood count, peripheral smear, erythrocyte sedimentation rate, C-reactive protein, biochemical tests, antinuclear antibodies, and HSV antibodies, all of which were negative. Bacterial cultures including those taken from the blister fluid showed no growth. Tzanck smear showed no viral inclusions. Histopathology of skin biopsy from the right hand revealed hemorrhagic intraepidermal bulla with vascular thrombosis which was nonimmune mediated (negative for IgG, IgM, IgA, C3, C1q on direct immunofluorescence) [ Figure 4 ].
The child was also receiving phenytoin for status epilepticus. Acyclovir was stopped following which there were no new eruptions. Thus, acyclovir was presumed to be the causative agent. The causal relationship was further supported by Naranjo algorithm, with a "definite" adverse reaction score of 9 [ Tables 1 and 2 ]. [4] 
Discussion
Acyclovir is a guanine analog antiviral drug, primarily used for the treatment of HSV and varicella-zoster virus infections. [5] Acyclovir is considered a prodrug, which is converted into a monophosphate by viral thymidine kinase which gets converted to the active triphosphate form, acyclo-guanosine tri-phosphatase (GTP) by cellular kinases. Acyclo-GTP is a highly potent inhibitor of viral DNA polymerase. The elimination half-life of acyclovir is approximately three hours. [3] Systemic adverse effects following intravenous acyclovir administration are very rare. Few local dermatological adverse effects known are phlebitis and inflammation at the infusion site. [1, 2] However, bullous eruptions following acyclovir infusion are very rare, with only a handful of case reports mentioned in literature so far.
Armingaud et al. have proposed an immunoallergic mechanism to explain the pathogenesis of the eruption. The biopsy of the vesicular lesion away from the injection site revealed leukocytoclastic vasculitis in their study. [6] These lesions mimic herpetic lesions grossly, 
Questions
Score Are there previous conclusive reports on this reaction? Yes (+1)/no (0)/do not know or not done (0) Did the adverse events appear after the suspected drug was given?
Yes (+2)/no (−1)/do not know or not done (0) Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given?
Yes (+1)/no (0)/do not know or not done (0)
Did the adverse reaction appear when the drug was re-administered?
Yes (+2)/no (−1)/do not know or not done (0) Are there alternative causes that could have caused the reaction?
Yes (−1)/no (+2)/do not know or not done (0) Did the reaction reappear when a placebo was given?
Yes (−1)/no (+1)/do not know or not done (0) Was the drug detected in any body fluid in toxic concentrations?
Yes (+1)/no (0)/do not know or not done (0) Was the reaction more severe when the dose was increased or less severe when the dose was decreased?
Did the patient have a similar reaction to the same or similar drugs in any previous exposure?
Was the adverse event confirmed by any objective evidence?
Yes (+1)/no (0)/do not know or not done (0) Total score=9 (definite ADR). ADR -Adverse drug reaction 
: (a) Intraepidermal cleft containing red blood cells and few inflammatory cells (arrow) (H and E, ×40). (b) Intraepidermal cleft showing red blood cells (H and E, ×400)
b a and hence, thorough evaluation is required for their differentiation. [2] Conclusion Bullous eruptions along the infusion site should be considered as a potential adverse effect after acyclovir administration, and a vigilant approach is indispensable for appropriate treatment and differentiation from other infectious etiologies.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest. 
